Molecular sampling of prostate cancer: a dilemma for predicting disease progression. - Test2 - elhamkhani - TriplyDB

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

http://www.wikidata.org/entity/Q33541296

about

Validation of proposed prostate cancer biomarkers with gene expression data: a long road to travel Expression differences between African American and Caucasian prostate cancer tissue reveals that stroma is the site of aggressive changes PhysioSpace: relating gene expression experiments from heterogeneous sources using shared physiological processes Transcriptional signatures of Ral GTPase are associated with aggressive clinicopathologic characteristics in human cancer.Loss of p63 and its microRNA-205 target results in enhanced cell migration and metastasis in prostate cancer Constructing Bayesian networks by integrating gene expression and copy number data identifies NLGN4Y as a novel regulator of prostate cancer progression.Computational identification of mutually exclusive transcriptional drivers dysregulating metastatic microRNAs in prostate cancer Evaluation of ERG responsive proteome in prostate cancer Copy number alteration burden predicts prostate cancer relapse Genome-wide expression assay comparison across frozen and fixed postmortem brain tissue samples.Molecular profiling of indolent human prostate cancer: tackling technical challenges to achieve high-fidelity genome-wide data.SPDEF inhibits prostate carcinogenesis by disrupting a positive feedback loop in regulation of the Foxm1 oncogene.Algebraic comparison of partial lists in bioinformatics Detecting microRNAs of high influence on protein functional interaction networks: a prostate cancer case study.Discovery of non-ETS gene fusions in human prostate cancer using next-generation RNA sequencing.The Thoc1 ribonucleoprotein and prostate cancer progression.Curation-free biomodules mechanisms in prostate cancer predict recurrent disease.mRNA expression signature of Gleason grade predicts lethal prostate cancer The biology of castration-resistant prostate cancer Protein-coding and microRNA biomarkers of recurrence of prostate cancer following radical prostatectomy Coordinate microRNA-mediated regulation of protein complexes in prostate cancer.Protein-network modeling of prostate cancer gene signatures reveals essential pathways in disease recurrence.Gene signatures ESC, MYC and ERG-fusion are early markers of a potentially dangerous subtype of prostate cancer.Semi-supervised adaptive-height snipping of the hierarchical clustering tree.Profiling prostate cancer.Molecular classification of prostate cancer using curated expression signatures MetaQC: objective quality control and inclusion/exclusion criteria for genomic meta-analysis.Computational Reconstruction of NFκB Pathway Interaction Mechanisms during Prostate Cancer.Novel Gene Expression Signature Predictive of Clinical Recurrence After Radical Prostatectomy in Early Stage Prostate Cancer Patients.Molecular differences in transition zone and peripheral zone prostate tumors.Predicting Drug Response in Human Prostate Cancer from Preclinical Analysis of In Vivo Mouse Models.Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer MicroRNA-106b-25 cluster expression is associated with early disease recurrence and targets caspase-7 and focal adhesion in human prostate cancer.Integrative analysis of breast cancer reveals prognostic haematopoietic activity and patient-specific immune response profiles Roles of Distal and Genic Methylation in the Development of Prostate Tumorigenesis Revealed by Genome-wide DNA Methylation Analysis Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue.Development and validation of a 32-gene prognostic index for prostate cancer progression.Evaluating a 4-marker signature of aggressive prostate cancer using time-dependent AUC.The TMPRSS2:ERG rearrangement, ERG expression, and prostate cancer outcomes: a cohort study and meta-analysis Molecular circuit involving KLK4 integrates androgen and mTOR signaling in prostate cancer.

P2860

Q27001399-F4BEE307-E44D-46F4-9DCD-8217988AF4F5 Q28292423-17AF8355-7718-4197-8232-9F155AE19A4E Q28534493-B0190A7A-C657-48FA-BDA9-E4CA3282CAB7 Q30416201-838364D4-864A-48B0-A3FA-6DEC94ECFB03 Q30525287-412DB04D-6CD3-4129-8590-3022CD3BDE27 Q31130674-E50C144F-A902-444A-9468-1AC89F058940 Q33571906-0F4CCF5A-0BAA-4134-9D38-9A39C27EE5F7 Q33822319-461677F7-A722-4945-9856-721DB96F14C1 Q34002312-639B7383-02E8-4E96-81EB-544F73FACD7F Q34015378-1632DB09-D8B7-4D66-AC9E-5BCEF2BC80DD Q34151167-5CA6F23D-2A29-467D-B21C-C4CEA012A1BD Q34257025-78E71F6C-D85E-488D-AE57-6530AF59783A Q34277314-F6012C8B-BCD7-4FB8-8D5C-659467B260CA Q34396793-174011D2-9BFD-44DA-9E8B-DAE0949617F2 Q34452282-93D1518F-2959-4257-BD61-18F7C4AB1FE3 Q34736122-BA3F4BFB-E772-4BEB-8237-698B4BF92819 Q34790757-3FBBC12A-20BE-4C7C-BD39-77D114EE2CF8 Q35023464-0C3A5114-1878-4654-BDFC-B16C591E7F4A Q35039889-2044B765-F706-4C4D-80D5-330A4DD1BEAF Q35070161-56D649EE-E9A2-4467-8BF2-4FD207F5C5A8 Q35082892-D4C320F0-8522-4D88-BED1-B0BCD0F017BA Q35082989-A4069BFF-DFC2-42C0-92C7-BB90AF14B0E7 Q35223291-20D6C514-C83F-4EB9-9C2A-0EADEEB103CE Q35543589-62819BD5-836E-4B54-9BAD-80AE265CFABB Q35641430-214BDC26-D7C1-4826-8AC9-C696AE7538AC Q35641563-376B2D77-813E-4EB5-B587-FC068442DF2E Q35672164-4FCC7145-B281-410B-AD43-FAF182D81DB4 Q35989733-1B999177-0D10-455B-BC62-4B28DEEE567D Q36043833-5515CFA9-92FA-4A94-B950-035FA75F6C8C Q36067907-76CD3408-0180-4570-9538-3BF1D9D5C8BC Q36113762-A526CB34-4955-431B-BBF6-92DBC9CD9DF7 Q36199762-C7CEF1F1-EBBD-4221-98F3-A7D974F0A119 Q36488217-53FC6EFB-C6D2-4B0C-806A-08106EEAE7E7 Q36499105-0A18D1E4-D2BD-4707-AD22-48EEA244D7DE Q36628603-3CE9B007-D9FC-48D7-BDED-0F674770700B Q36661317-3691E042-87F4-4924-ADE5-048CAE2F432F Q36762398-6CCFE93E-AE1B-4743-91B5-524571A5BD8C Q36797979-1655DA8A-9485-45F1-9220-B92458377629 Q36899790-27D1D2E2-39DC-446F-B8B6-6FB7EE6057CA Q37010879-F5CC1100-179D-4BC2-B125-D07A352B6489

P2860

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

http://www.wikidata.org/entity/Q33541296

description

2010 nî lūn-bûn

@nan

2010 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի մարտին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

@ast

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

@en

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

@nl

type

label

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

@ast

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

@en

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

@nl

prefLabel

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

@ast

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

@en

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

@nl

P1433

Q33541296-6C840F77-1DC3-4D20-99F0-8A6CFEBDE4C0

P1476

Q33541296-17300BCC-3918-4ABA-A695-3E402495FEDC

P2093

Q33541296-089BFF41-68C4-4A42-A9A4-D2407AF6CA8B

Q33541296-3B9C5AF4-3758-4A7E-AAEF-6B3DD33D8650

Q33541296-42892B3F-D1A1-489C-9408-1DFF589D294C

Q33541296-5E3F80DD-1B5B-4214-A963-AFC04DA144DF

Q33541296-6334013F-849C-4B9C-9467-839EB463B755

Q33541296-B7EC7360-67A6-4F70-AFB8-C940C32DF2F6

Q33541296-C85B7B10-486F-42D3-BB31-383390D59F51

Q33541296-D57B47A0-6C16-4B72-BE48-51531E6CCBB5

Q33541296-F993B7D6-F777-4F2D-872B-886EB92FA390

P2860

Q33541296-07C92A7D-215B-461E-B58E-7F7445697879

Q33541296-14BBA6B5-5772-4625-98A0-6B1375A486F0

Q33541296-16033CCB-8D07-4146-BB91-7F8884EA4CFD

Q33541296-189B75AD-3058-45FA-B85F-2F6FB4F39F57

Q33541296-1EE5BB62-B7B8-4599-A8F6-1AD0E24A5C5F

Q33541296-1F3301D9-1793-460F-904C-CC9835458729

Q33541296-24A30D75-905B-484B-BEF8-62A0504787E8

Q33541296-2674486B-7925-40F3-80AC-FEE375732270

Q33541296-2A90F051-293C-4D87-A0D1-CCD95C8C02E6

Q33541296-32D9FE53-BE64-4E64-80E5-4ECCBA7DEDB6

P2888

Q33541296-D7FE1657-E897-459B-944A-639C82FE43E9

P304

Q33541296-669711FA-D808-46F2-AFB5-53C6FF530D11

P31

Q33541296-F30EB99A-F498-4C9E-BB5C-8CC7AA3B15A6

P356

Q33541296-8964DBEB-1C25-49B5-A103-6BB7045B96BD

P478

Q33541296-95B22B86-CCD0-4ED7-9579-CA236347D1BA

P50

Q33541296-27905887-A46F-4EA4-9ACF-2B5D0F1B108D

Q33541296-3287FB1B-E38D-4D8F-ADA8-EFBED27DF090

Q33541296-33A51386-3632-472D-80EE-6A588366D400

Q33541296-415C6FA6-F3B4-410D-8CE9-F58938DFBD39

Q33541296-6170735D-FBC4-45AD-9D96-CD237C73E31C

Q33541296-A0EE5F35-1D10-41B1-95F0-6FB1B820A0F5

Q33541296-C2748A05-1CCA-4E14-8284-D217D7E60B17

Q33541296-C564983C-2BC2-4280-8552-B4F4EC3D5B21

Q33541296-D49097D0-76EF-4E3C-9969-2C83F06719AE

Q33541296-E833C886-D48E-419D-8038-5A75A7430B18

P577

Q33541296-AD0E5885-A393-413B-B766-8B2203C13E4E

P5875

Q33541296-F27B437B-E263-4DCB-96A2-35B6681542C2

P6179

Q33541296-717DD2C5-D7BD-4D57-9A16-23612B4BDF9D

P698

Q33541296-D70674C4-DCDB-4A7D-A242-5F2B0476E062

P932

Q33541296-2E60AE12-CA51-4C8E-928E-E25218186729

P356

P1433

BMC Medical Genomics

P1476

Molecular sampling of prostate cancer: a dilemma for predicting disease progression.

@en

P2093

Eberhard Varenhorst

http://www.w3.org/2001/XMLSchema#string

Jan-Erik Johansson

http://www.w3.org/2001/XMLSchema#string

Ove Andrén

http://www.w3.org/2001/XMLSchema#string

Sunita R Setlur

http://www.w3.org/2001/XMLSchema#string

Sven Perner

http://www.w3.org/2001/XMLSchema#string

Swen-Olof Andersson

http://www.w3.org/2001/XMLSchema#string

Todd R Golub

http://www.w3.org/2001/XMLSchema#string

Yudi Pawitan

http://www.w3.org/2001/XMLSchema#string

Yujin Hoshida

http://www.w3.org/2001/XMLSchema#string

P2860

Bias in error estimation when using cross-validation for model selection

Microarray analysis identifies a death-from-cancer signature predicting therapy failure in patients with multiple types of cancer

Gene expression profiling predicts clinical outcome of prostate cancer

Isolation of rare circulating tumour cells in cancer patients by microchip technology

Mortality results from a randomized prostate-cancer screening trial

Cancer statistics, 2008

Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications

Molecular classification of cancer: class discovery and class prediction by gene expression monitoring

Detection of mutations in EGFR in circulating lung-cancer cells

Classification of human lung carcinomas by mRNA expression profiling reveals distinct adenocarcinoma subclasses

P2888

P304

8

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/1755-8794-3-8

http://www.w3.org/2001/XMLSchema#string

P478

3

http://www.w3.org/2001/XMLSchema#string

P50

Francesca Demichelis

Philip W. Kantoff

Hans-Olov Adami

Lorelei A Mucci

Mark Bender Gerstein

Meir J Stampfer

P577

2010-03-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

42108506

http://www.w3.org/2001/XMLSchema#string

P6179

1029841285

http://www.w3.org/2001/XMLSchema#string

P698

20233430

http://www.w3.org/2001/XMLSchema#string

P932

2855514

http://www.w3.org/2001/XMLSchema#string